Biogen Stock And The Aduhelm Drama — Will It Really Treat Alzheimers? – Investors Business Daily

It may not be fair, but the fate of Biogen stock is now intricately tied to the success or failure of its controversial Alzheimer’s treatment, Aduhelm. It’s a future that looks increasingly cloudy.
… [+7884 chars]